key: cord-0682055-zu4hh4ql
authors: Fallahzadeh, Mohammad; Pourhoseingholi, Mohamad A.; Boroujeni, Masoud G.; Besharati, Sajad; Mardani, Masoud; Shabani, Minoosh; Shokouhi, Shervin; Amirdosara, Mahdi; Hajiesmaeili, Mohammadreza; Gachkar, Latif; Roshan, Baran; Zangi, Masoud; Mirmomeni, Golshan; Irvani, Seyed S. N.; Alavi Darazam, Ilad
title: Study of the effects of interferon β−1a on hospitalized patients with COVID‐19: SBMU Taskforce on the COVIFERON study
date: 2021-11-30
journal: J Med Virol
DOI: 10.1002/jmv.27475
sha: b52a178642e4ec2eb4bba4750ffc298d9bc34a7d
doc_id: 682055
cord_uid: zu4hh4ql

Interferons are an essential part of the innate immune system and have antiviral and immunomodulatory functions. We studied the effects of interferon β‐1a on the outcomes of severe cases of coronavirus disease 2019 (COVID‐19). This retrospective study was conducted on hospitalized COVID‐19 patients in Loghman‐Hakim hospital from February 20, 2020 to April 20, 2020, Tehran, Iran. Patients were selected from two groups, the first group received interferon β‐1a in addition to the standard treatment regimen, and the second group received standard care. The clinical progression of two groups during their hospital admission was compared. We studied a total number of 395 hospitalized COVID‐19 patients. Out of this number, 111 patients (33.5%) died (31.3% of the interferon β‐1a group and 34.1% of the control group). The mortality rate indicated no statistically significant difference between groups (p‐value = 0.348), however for patients who were hospitalized for more than a week, the rate of mortality was lower in the interferon β‐1a group (p‐value = 0.014). The median hospital stay was statistically longer for patients treated by interferon β‐1a (p‐value < 0.001). The results of this study showed that interferon β‐1a can improve the outcomes of hospitalized patients with severe COVID‐19, but more adequately‐powered randomized controlled trials should be conducted.

In December 2019, a new virus belonging to the coronaviridea family was reported in Wuhan, China, which was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus caused a global outbreak of a respiratory disease known as coronavirus disease 2019 (COVID- 19) . 1 COVID-19 has a wide range of symptoms including mild self-limited disease to severe progressing pneumonia and multiple organ failure. [2] [3] [4] The high rate of transmission and mortality (3.7%) of this disease 5 made it a public health emergency of international concern (PHEIC). 6 Clinical researchers made efforts to find a specific treatment for COVID-19, and have suggested some kind of medications for the management of this disease. 7, 8 The efficacy of different categories of drugs have been evaluated in clinical trials and some medications had relative efficacy. 9 The emergency condition of the COVID-19 pandemic and lack of available drugs of proven efficacy for COVID-19 caused to repurpose drugs for treating COVID-19 which were used for other purposes previously. 10 Various pharmacological interventions were suggested to treat COVID-19, however, their efficiency is questionable. Some antiviral agents, including remdesivir and combination of lopinavir and ritonavir, and immunomodulatory drugs, consisting of corticosteroids, hydroxychloroquine, and interferons, have been used in COVID-19 patents. [11] [12] [13] [14] [15] [16] The innate immune response plays an important role in novel viral infections without previous established adaptive immunity to the pathogen to downturn the severity of the disease. 17 Interferons are an essential part of this immune action and have antiviral and immunomodulatory functions. 17 In a recent clinical trial, interferon beta1a (IFN-β1a) had significant efficacy in patients with Previous in vitro investigations showed the antiviral effect of interferon-β against the SARS virus. 18 In this retrospective study, we assessed the clinical results of IFN-β1a in severe cases of COVID-19.

This retrospective study was conducted on hospitalized COVID-19 patients in Loghman-Hakim hospital from February 20, 2020 to April 20, 2020, Tehran, Iran. This study started after research ethics committee approval. Patients were selected from two groups with different treatment regimens for COVID-19, which were matched, based on age, sex, and severity of disease regarding arterial oxygen saturation. Patients of the first group received interferon β-1a (IFN-β1a) (Recigen) in addition to standard treatment regimen and patients of the second group received standard care. We obtained demographic characteristics, background health conditions, clinical symptoms, and signs, and laboratory and imaging findings of patients.

We studied patients with COVID-19 which was confirmed by positive polymerase chain reactions (PCRs) and positive chest computed tomography (CT) scans. All patients had clinical symptoms accordant with COVID-19. Participants were hospitalized in the ward or intense care unit of Loghman Hospital due to severe COVID-19 pneumonia.

Severe COVID-19 was defined as patients with arterial blood oxygen saturation level less than 90 percent in the initial assessment and who suffer from moderate to severe dyspnea, based on patients' assessment. Some of these patients had received IFN-β1a in addition to standard treatment regimen and the rest had received just standard care. Patients of these two groups were matched, based on age, sex, and the severity of the disease. Clinical information of patients has been extracted from Loghman-Hakim hospital central database.

In this study, the patients were selected from two groups. Both groups received medication based on the protocol of the health ministry of Iran for COVID-19 including lopinavir/ritonavir (400 mg/ 100 mg twice a day for 10 days) (Kaletra) + hydroxychloroquine (400 mg single dose). This treatment regimen was based on Iran's internal guideline for COVID-19 in February 2020, when we initiated this study. 19 Patients of the first group also received IFN-β1a (subcutaneous injections of 44 µg (12 000 000 IU) on Days 1, 3, and 5), (Recigen).

We studied the clinical progression of two groups during their hospital admission. The mortality rate in the early 7 days and in the late phase of admission, duration of hospital admission, arterial blood gas findings, complete blood count findings, C-reactive protein, and erythrocyte sedimentation rate have been compared between two groups.

Frequency rates and percentages were used for categorical variables, and interquartile ranges (IQRs) and median were used for continuous variables. For comparison of the non-normal continuous variables, the Kruskal-Wallis test was used. χ 2 test was used for comparing the frequency of categorical variables and a logistic regression model was also applied to calculate the odds ratios (ORs) with 95% confidence intervals (CIs). R software version 3.6.1 was used to perform the statistical analyses. 

This study revealed that IFN-β1a decreased the days of hospitalization and the mortality rate in severe COVID-19 patients who had been hospitalized for more than 7 days.

The mortality rate in severe COVID-19 patients was reported between 62% and 81%. 20 A recent study showed COVID-19 patients with more severe disease had significantly decreased interferon activity and SARS-CoV-2 suppressed IFN-β release in vitro. 21, 22 There is an increased risk of severe lung disease in people with comorbidities, older age, or who receive immunosuppressive medication due to less IFN-β production. 23, 24 IFN-β is superior to other interferons in inhibition of coronaviruses replication. 25 It should be used in the early phase of viral infection to reach a protective effect and late application of interferon may exacerbate the disease. 26, 27 IFN-β increases CD73 which plays a role in vascular integrity in hypoxic conditions. 28 A high serum level of interferon is needed to reach an antiviral effect. 27 Long-term safety and tolerability of IFN-β are proven due to its application in multiple sclerosis treatment. 29 In our study, the two groups didn't have a significant difference in mortality rate; however, in patients who were hospitalized for more than a week, the rate of mortality was lower in the Recigen group, compared to those corresponding ones who received standard care. In addition, the median hospital stay was statistically longer for patients treated by IFN-β1a.

In a previous randomized trial, a combination of INF-β with lopinavir/ritonavir and ribavirin was safe, alleviated the symptoms, and shortened the duration of hospital stay compared with triple antiviral therapy alone. 30 In another trial, IFN-β significantly improved the discharge rate and lowered the 28-day mortality, especially in patients who received it in the early phase of the disease. 31 We had some limitations in this study. The most important limitation is that this study was conducted in the critical phase of the 

The authors declare that there are no conflict of interests. 

The data presented in the manuscript could be available for the journal.

Ilad Alavi Darazam http://orcid.org/0000-0002-4440-335X

A novel coronavirus from patients with pneumonia in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Coronavirus disease 2019 (COVID-19): situation report

Laboratory findings, signs and symptoms, clinical outcomes of Patients with COVID-19 Infection: an updated systematic review and meta-analysis

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

World Health Organization Solidarity" clinical trial for COVID-19 treatments. World Health Organization (WHO) Situation reports Geneva: WHO

Antiviral treatment of COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR

Di Napoli R. Features, evaluation, and treatment of coronavirus

Remdesivir for the Treatment of Covid-19 -Final Report

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Type I interferons: distinct biological activities and current applications for viral infection

SARS: systematic review of treatment effects

Iran's approach to COVID-19: evolving treatment protocols and ongoing clinical trials. Front Public Health

Clinical course and mortality risk of severe COVID-19. The Lancet

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

et alImpaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients

Mechanisms and implications of age-associated impaired innate interferon secretion by dendritic cells: a mini-review

Antiviral immunity is impaired in COPD patients with frequent exacerbations

The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein

Interferon beta-1a for COVID-19: critical importance of the administration route

Interferons in the therapy of severe coronavirus infections: a critical analysis and recollection of a forgotten therapeutic regimen with interferon beta

The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. The Lancet Respiratory Medicine

PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet

A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19